Delcath Systems, Inc. (DCTH)
Chart Events
Performance Outlook
| Previous Close | 4.1200 |
| Open | 4.1200 |
| Bid | 4.0200 x 1000 |
| Ask | 4.0400 x 800 |
| Day's Range | 3.9800 - 4.2450 |
| 52 Week Range | 2.3400 - 7.9900 |
| Volume | |
| Avg. Volume | 2,254,303 |
| Market Cap | 61.717M |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.0800 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.80 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DCTH
Related Research
- Delcath Systems, Inc.Analyst Report: Bristol-Myers Squibb Co.Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500.RatingFair ValueEconomic Moat6 days agoArgus Research
TipRanksThese 2 “Strong Buy” Penny Stocks Could Soar to $17 (Or Higher), Say Analysts
Let’s take a moment to talk about opportunity, share price, and risk/reward considerations. These are some of the factors investors must consider when moving into penny stocks – and we haven’t even touched on the fundamental soundness of the company or its business model. Penny stocks – as their name suggests, they once traded for just a pennies per share, but these days are considered those equities trading at less than $5 – are a challenging market niche. The penny stock critics make valid poi
PR NewswireA Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the details of an oral presentation by independent investigators on September 9, 2023 at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting held in Copenhagen, Denmark.
- PR Newswire
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25th Annual Global Investor Conference. Delcath CEO, Gerard Michel will present on September 13 at 11:00 AM ET.
